CN1434720A - 用于治疗和预防与异常血凝固有关的疾病的药用组合物 - Google Patents
用于治疗和预防与异常血凝固有关的疾病的药用组合物 Download PDFInfo
- Publication number
- CN1434720A CN1434720A CN00819097A CN00819097A CN1434720A CN 1434720 A CN1434720 A CN 1434720A CN 00819097 A CN00819097 A CN 00819097A CN 00819097 A CN00819097 A CN 00819097A CN 1434720 A CN1434720 A CN 1434720A
- Authority
- CN
- China
- Prior art keywords
- blood coagulation
- fviia
- factor
- blood
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
- 230000023555 blood coagulation Effects 0.000 title abstract description 11
- 230000002159 abnormal effect Effects 0.000 title abstract description 3
- 201000010099 disease Diseases 0.000 title description 5
- 108010014173 Factor X Proteins 0.000 claims abstract description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 6
- 239000003114 blood coagulation factor Substances 0.000 claims abstract description 6
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims abstract description 4
- 239000003112 inhibitor Substances 0.000 claims description 24
- 208000032843 Hemorrhage Diseases 0.000 claims description 22
- 230000023597 hemostasis Effects 0.000 claims description 22
- 230000004913 activation Effects 0.000 claims description 17
- 208000015294 blood coagulation disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108090000190 Thrombin Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229960004072 thrombin Drugs 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 8
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 6
- 108010023321 Factor VII Proteins 0.000 claims description 6
- 229940012413 factor vii Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 21
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000005856 abnormality Effects 0.000 abstract description 2
- 229940019700 blood coagulation factors Drugs 0.000 abstract description 2
- 108010054265 Factor VIIa Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002008 hemorrhagic effect Effects 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 27
- 102100022641 Coagulation factor IX Human genes 0.000 description 20
- 238000013459 approach Methods 0.000 description 16
- 208000034158 bleeding Diseases 0.000 description 15
- 230000000740 bleeding effect Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 208000009429 hemophilia B Diseases 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 12
- 229960004222 factor ix Drugs 0.000 description 8
- 102100026735 Coagulation factor VIII Human genes 0.000 description 7
- 208000009292 Hemophilia A Diseases 0.000 description 7
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108010076282 Factor IX Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 208000031220 Hemophilia Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229910001424 calcium ion Inorganic materials 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 238000009256 replacement therapy Methods 0.000 description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108010079356 FIIa Proteins 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP368122/1999 | 1999-12-24 | ||
JP36812299A JP4676585B2 (ja) | 1999-12-24 | 1999-12-24 | 血液凝固異常に基づく疾患の治療・予防用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1434720A true CN1434720A (zh) | 2003-08-06 |
CN1222311C CN1222311C (zh) | 2005-10-12 |
Family
ID=18491024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008190976A Expired - Lifetime CN1222311C (zh) | 1999-12-24 | 2000-12-21 | 用于治疗和预防与异常血凝固有关的疾病的药用组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6881721B2 (zh) |
EP (1) | EP1240901B1 (zh) |
JP (1) | JP4676585B2 (zh) |
CN (1) | CN1222311C (zh) |
AT (1) | ATE407692T1 (zh) |
DE (1) | DE60040236D1 (zh) |
DK (1) | DK1240901T3 (zh) |
ES (1) | ES2312374T3 (zh) |
WO (1) | WO2001047548A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1407780T3 (da) * | 2001-07-10 | 2013-05-13 | Chemo Sero Therapeut Res Inst | Farmaceutisk stabile hæmostatiske præparater |
JP2007055899A (ja) * | 2003-10-27 | 2007-03-08 | Chemo Sero Therapeut Res Inst | 血液凝固第x因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物 |
US20090053193A1 (en) * | 2004-05-11 | 2009-02-26 | Novo Nordisk Healthcare A/G | Use of Factor VIIa for the Treatment of Burn Trauma |
WO2008023052A1 (en) * | 2006-08-24 | 2008-02-28 | Novo Nordisk Health Care Ag | Combination of a fvii and a thrombin-activable factor x |
EP2201953A4 (en) * | 2007-08-27 | 2011-08-03 | Univ Nagoya Nat Univ Corp | USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER |
US10147152B2 (en) | 2010-04-08 | 2018-12-04 | Hemosonics, Llc | Hemostatic parameter display |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0044343B1 (en) | 1980-01-28 | 1984-08-22 | Baxter Travenol Laboratories, Inc. | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
US4287180A (en) * | 1980-01-28 | 1981-09-01 | Baxter Travenol Laboratories, Inc. | Method for treating blood clotting factor inhibitors |
US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
US4286056A (en) * | 1980-01-28 | 1981-08-25 | Baxter Travenol Laboratories, Inc. | Method for making therapeutic enzyme compositions |
US4357321A (en) * | 1980-01-28 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for treating clotting factor inhibitors |
US4459288A (en) * | 1981-05-11 | 1984-07-10 | Baxter Travenol Laboratories, Inc. | Therapeutic blood clotting factor compositions and their use |
US4382083A (en) * | 1981-06-25 | 1983-05-03 | Baxter Travenol Laboratories, Inc. | Therapeutic method for treating blood-clotting defects with factor VIIa |
US4501731A (en) * | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
JP2824430B2 (ja) | 1989-08-02 | 1998-11-11 | 財団法人化学及血清療法研究所 | 血液凝固第▲vii▼因子または活性型血液凝固第▲vii▼因子の調製方法 |
DE4325872C1 (de) | 1993-08-02 | 1994-08-04 | Immuno Ag | Virusinaktivierte Faktor Xa-Präparation |
AU697205B2 (en) * | 1994-04-22 | 1998-10-01 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Method and means for detecting and treating disorders in the blood coagulation cascade |
DE19531637A1 (de) | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
JP4046377B2 (ja) | 1996-08-19 | 2008-02-13 | 財団法人化学及血清療法研究所 | 血液凝固第vii因子の活性化方法及び該方法に基づく活性化血液凝固第vii因子の製造方法 |
JPH1059866A (ja) | 1996-08-19 | 1998-03-03 | Chemo Sero Therapeut Res Inst | 血液凝固第vii因子及び/もしくは活性化血液凝固第vii因子の製造方法 |
-
1999
- 1999-12-24 JP JP36812299A patent/JP4676585B2/ja not_active Expired - Lifetime
-
2000
- 2000-12-21 DK DK00987688T patent/DK1240901T3/da active
- 2000-12-21 CN CNB008190976A patent/CN1222311C/zh not_active Expired - Lifetime
- 2000-12-21 DE DE60040236T patent/DE60040236D1/de not_active Expired - Lifetime
- 2000-12-21 AT AT00987688T patent/ATE407692T1/de active
- 2000-12-21 US US10/168,371 patent/US6881721B2/en not_active Expired - Lifetime
- 2000-12-21 EP EP00987688A patent/EP1240901B1/en not_active Expired - Lifetime
- 2000-12-21 ES ES00987688T patent/ES2312374T3/es not_active Expired - Lifetime
- 2000-12-21 WO PCT/JP2000/009102 patent/WO2001047548A1/ja active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP4676585B2 (ja) | 2011-04-27 |
WO2001047548A1 (fr) | 2001-07-05 |
JP2001181204A (ja) | 2001-07-03 |
US6881721B2 (en) | 2005-04-19 |
CN1222311C (zh) | 2005-10-12 |
EP1240901B1 (en) | 2008-09-10 |
DK1240901T3 (da) | 2008-11-10 |
DE60040236D1 (de) | 2008-10-23 |
US20030060411A1 (en) | 2003-03-27 |
EP1240901A4 (en) | 2005-01-12 |
EP1240901A1 (en) | 2002-09-18 |
ATE407692T1 (de) | 2008-09-15 |
ES2312374T3 (es) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0082182B1 (en) | Composition based on the hemostatic agent factor viia and method of preparing same | |
Shibagaki et al. | Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? | |
US4456591A (en) | Therapeutic method for activating factor VII | |
US7425539B2 (en) | Factor IXa for the treatment of bleeding disorders | |
Van Wyk et al. | A comparison between the use of recombinant hirudin and heparin during hemodialysis | |
Smith et al. | Polyphosphate as a general procoagulant agent | |
Macik et al. | Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study | |
Hedner | Factor VIIa and its potential therapeutic use in bleeding-associated pathologies | |
RU2003127018A (ru) | Комбинированное применение полипептидов фактора vii и полипептидов фактора viii | |
US4479938A (en) | Therapeutic composition containing factor VIIa | |
WO2009061697A1 (en) | Anticoagulant antagonist and hemophilia procoagulant | |
JPH01193229A (ja) | 抗血液凝固剤 | |
US7291333B1 (en) | Blockade of protein C activation reduces microvascular surgical blood loss | |
CN1222311C (zh) | 用于治疗和预防与异常血凝固有关的疾病的药用组合物 | |
Glazer et al. | Clinical update on the use of recombinant factor VII | |
EP3833381B1 (en) | Modified factor vii polypeptides for subcutaneous administration | |
KR20230027277A (ko) | 혈우병을 치료하기 위한 방법 및 조성물 | |
CN101291686B (zh) | 作为新的局部用抗出血剂的活化的因子X(FXa)的刺激剂 | |
Mattsson et al. | Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis | |
JPH08208504A (ja) | 抗血栓および血栓溶解療法と組み合わせて適用する治療法としてのvWF−含有濃縮物の使用 | |
Maraganore | Pre-clinical and clinical studies on hirulog: a potent and specific direct thrombin inhibitor | |
Schulman | Haemostatic and replacement therapy in von Willebrand disease | |
WO2005039628A1 (ja) | 血液凝固第x因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物 | |
Turecek et al. | Factor eight inhibitor bypassing activity | |
CA2465004A1 (en) | Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Xiongben County, Xiongben, Japan Patentee after: THE CHEMO-SERO-THERAPEUTIC Research Institute Address before: Kumamoto Prefecture, Japan Patentee before: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC Research Institute |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200309 Address after: Kumamoto, Japan Patentee after: THE CHEMO-SERO-THERAPEUTIC Research Institute Address before: Xiongben County, Xiongben, Japan Patentee before: THE CHEMO-SERO-THERAPEUTIC Research Institute |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20051012 |